LAUSR

The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2–4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3–4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8–81.7) for good, 51.0 (44.1–57.8) for intermediate good, 32.2 (26.2–38.2) for intermediate poor, and 18.9 (15.1–22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09–1.84) for intermediate good, 2.58 (2.00–3.33) for intermediate poor, and 3.88 (2.94–5.10) for poor. Time to progression showed medians (months) 20.5 (17.4–62.4) for good, 19.3 (17.0–21.7) for intermediate good, 19.6 (16.2–23.0) for intermediate poor, and 13.0 (10.8–15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.